摘要
目的研究Polo样激酶1（polo-like kinase 1,PLK1）在直肠癌组织中的表达情况及临床意义。方法选取2010年12月至2014年8月中国医科大学附属盛京医院收治的直肠癌患者160例,应用免疫组织化学染色的方法,检测直肠癌组织及其周围正常组织中PLK1的表达情况,并分析PLK1与临床病理特征、5年生存率是否具有相关性。结果 PLK1在160例直肠癌中高表达率56.25%,30例周围正常组织中高表达率23.33%,PLK1在直肠癌组织及正常组织中表达存在差异（χ^2=10.954,P=0.037）。PLK1的表达水平与直肠癌患者性别、年龄、组织学分级、肿物大小、淋巴结情况无关（P〉0.05）,与TNM分期相关（P〈0.05）。肿瘤组织中PLK1低表达患者5年总生存率85.71%,PLK1高表达患者5年总生存率48.89%,PLK1低表达较高表达患者总生存期高（P=0.000）。COX单因素分析PLK1表达情况、淋巴结转移、TNM分期与预后相关（P〈0.05）。将PLK1、淋巴结、TNM分期纳入COX模型进行多变量分析,显示PLK1（HR=6.233,P=0.000）、淋巴结转移（HR=5.107,P=0.000）是直肠癌总生存率的独立的影响因素。结论 PLK1是直肠癌预后的独立影响因子,高表达PLK1直肠癌预后差,其表达水平影响直肠癌患者生存,是潜在的治疗靶点。
Objective To explore the expression and clinical significance of Polo-like kinase 1 （PLK1） in rectal cancer.Method 160 patients diagnosed rectal cancer and accepted systematic treatment in Shengjing Hospital of China Medical University from December 2010 to August 2014 were included. Immunohistochemistry was used to assess the expression of PLK1 in rectal cancer and their surrounding normal tissues.We also analysed whether PLK1 expression has correlation with clinicopathological variables and 5-year overall survival （OS）.Result The high expression of PLK1 in rectal cancer tissues is 56.25%, 23.33% in 30 surrounding normal tissues. There exists significant difference between cancer and normal tissues （χ2= 10.954,P=0.037）. The expression of PLK1 has no correlation with gender, age, histological grading, tumor size and nodal status （P〉0.05） and has significant correlation with TNM stage （P〈0.05）. The 5-year OS rate for PLK1 low expression patients is 85.71%, while 48.89% in PLK1 high expression group.COX univariate analysis showed that PLK1 expression,nodal status and TNM stage were associated with OS （P〈0.05）, whileCOX multivariate analysis showed high PLK1 expression （HR=6.233,P=0.000） and positive nodal status （HR=5.107,P=0.000） were independent predictive factors for rectal cancer patients long-time survival.Conclusion PLK1 expression is an independent predictive factor for rectal cancer. High PLK1 expression suggests bad prognosis.PLK1 is a potential therapy target for rectal cancer patients.
出处
《中国医刊》
CAS
2016年第5期50-54,共5页
Chinese Journal of Medicine
